Immunoflazidum pharmachologic effect:
Immunoflazidum - a drug with significant antiviral and immunostimulatory effects. Immunoflazidum contains active components of plant origin, including in the preparation consists of such biologically active substances such as carboxylic acids and flavonoids. The mechanism of action of the drug is based on the ability of flavonoids to inhibit the replication of viral DNA and RNA. In clinical studies confirmed the activity of the drug against herpes viruses, and the viruses that cause acute respiratory infections. Flavonoids inhibit virus-DNA polymerase enzyme, thymidine kinase, and reverse transcriptase. In addition, when using the drug Immunoflazidum marked inhibition of neuraminidase activity, stimulation of the synthesis of endogenous interferon, as well as violation of the synthesis of RNA viruses.
Immunoflazidum boosts the local immune response by increasing the levels of lactoferrin and sIgA in the respiratory mucosa.
The preparation may be used for a long time, since chronic administration of the drug Immunoflazidum not develop inhibition of the activity of alpha- and gamma-interferon. After a single application of syrup marked induction of interferon to 6 days with peak performance on the second day.
Immunoflazidum has strong antioxidant properties, reduces the activity of lipid peroxidation and inhibits free radical reactions. Because of this effect of a marked decrease of intoxication and normalization of regenerative processes.
Immunoflazidum prevents the development of chronic diseases on the background of latent viral infections due to potentiation of apoptosis-inducing agents.
Pharmacokinetics Immunoflazidum not represented.
Indications:
Immunoflazidum used as a means of prevention and treatment of acute respiratory viral infections and influenza (including an infection caused by the pandemic strain).
Immunoflazidum can be recommended in the complex therapy of bacterial complications developed after the flu or acute respiratory infections.
Syrup Immunoflazidum as an immunomodulator administered to patients with acute and chronic forms of viral infections.
Immunoflazidum mode of application:
Immunoflazidum taken orally. For dosing syrup it is recommended to use measuring cup provided in the kit. Before applying the syrup is recommended to shake the bottle. To achieve maximum therapeutic effect syrup Immunoflazidum recommended to take 20-30 minutes before meals. The duration of therapy, the scheme of application and dose of syrup Immunoflazidum determined by the physician.
Children under 1 year old are generally administered with 0.5 ml of the syrup twice a day.
Children between the ages of 1-2 years, usually administered 1 ml of the syrup twice a day.
Children between the ages of 2-4 years, usually administered 1.5 ml of the syrup twice a day, starting from the third therapy is recommended to increase the dose to 3 ml of the syrup twice a day.
Children between the ages of 4-6 years, usually 3 ml designate syrup twice a day, starting from the third therapy is recommended to increase the dose to 4 ml of the syrup twice a day.
Children between the ages of 6-9 years, usually administered 4 ml of the syrup twice a day, starting from the third therapy is recommended to increase the dose up to 5 ml syrup twice a day.
Children aged 9-12 years are usually prescribed to 5 ml of the syrup twice a day, starting from the third therapy is recommended to increase the dose up to 6 ml of the syrup twice a day.
The recommended duration of therapy for patients with acute respiratory diseases and influenza is 2 weeks.
The recommended duration of prophylactic administration during the epidemic of influenza and acute respiratory viral infections is 2 to 4 weeks, with an epidemic of pandemic influenza strain rate can be increased up to 6 weeks.
The recommended duration of therapy for patients with complications of acute respiratory diseases and influenza is 4 weeks.
In chronic viral diseases Immunoflazidum course of the drug can reach 26 weeks.
Immunoflazidum side effects:
Immunoflazidum usually good tolerated. In some cases, noted the development of vomiting, epigastric pain, nausea, defecation disorders, headache and fever for 3-10 day dosing Immunoflazidum. With the development of unwanted effects from the gastrointestinal tract Immunoflazidum syrup it should be taken 2 hours after a meal. With the development of hyperthermia dose should be reduced by half.
In patients with chronic gastroduodenitis during therapy Immunoflazidum syrup may develop acute gastroduodenitis or the development of gastroesophageal reflux.
In rare cases, also noted the development of hypersensitivity reactions including erythema, urticaria and pruritus.
Immunoflazidum contraindications:
Immunoflazidum not indicated in patients with known hypersensitivity to the components of the syrup.
Immunoflazidum not used for the treatment of patients with acute duodenal ulcer and stomach, as well as autoimmune diseases.
Immunoflazidum during pregnancy:
During pregnancy and lactation, the decision on appointment of the drug takes Immunoflazidum doctor.
Interaction with other drugs:
Immunoflazidum can be administered combined with antifungal, antiviral drugs and antibiotics.
Overdose:
Data on drug overdose Immunoflazidum not.
When high doses of syrup Immunoflazidum can expect the development of adverse effects on the gastrointestinal tract.
No specific antidote. With the development of symptoms of overdose shown holding therapy aimed at their elimination.
Product:
Syrup Immunoflazidum 50 or 125 ml in dark glass bottles or vials of dark polymer material is enclosed in a cardboard box 1 bottle complete with a metering device.
Immunoflazidum storage conditions:
Immunoflazidum fit for use for 2 years after graduation.
After first opening the vial Immunoflazidum drug can be used for no more than 30 days.
Immunoflazidum Syrup should be stored in rooms with ambient temperature of 15 to 25 degrees Celsius, protected from direct sunlight.
It is forbidden to freeze syrup.
Composition:
100 ml of syrup contain Immunoflazidum:
Proteflazid extract liquid (1: 1) obtained from vegetable raw materials - grass Calamagrostis ground pike and Soddy.
The extract contains flavonoids (calculated as rutin) at least 0.32 mg of carboxylic acids (based on malic acid) not less than 0.3 g
Additional ingredients, including sorbitol and ethanol.
Pharmacological group:
Antimicrobial and antiparasitic drugs
Antiviral drugs
Antiviral drugs other groups
New
New
New
New
New
New
